Crinetics Pharmaceuticals, Inc.

Welcome to the Krenetics Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. I would now like to turn the call over to Gayathri Daiwakar of Krenetics. Please go ahead.

Thank you, Operator. Hello, everyone, and welcome to Krenetics Earnings Call. Joining me today are Dr. Scott Struthers, Founder and Chief Executive Officer, and Mark Wilson, Chief Financial Officer. Also joining us for the Q&A portion of the call are Dr. Dana Pizzuti, Chief Medical and Development Officer, and Dr. Alan Krasner, Chief Endocrinologist. A press release announced in the third quarter of 2024 financial results was issued today and is also available on our corporate website. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guaranteed performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Connecticut SEC filings, including its annual report on Form 10-K and quarterly reports on 10-Q. I would also like to specify that the content of this conference call contains time-centered information that is accurate only as of the date of this live broadcast, November 12, 2024. Clinetics take no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I'll turn the call over to Scott.

Thank you, Gayatri. Good afternoon, everyone, and thank you for joining us on our third quarter 2024 results call. We've had yet another incredibly productive quarter with advancements up and down the pipeline, and we continue to strengthen our financial position. For today's call, I will summarize our recent accomplishments shown on slide three, preview some of our upcoming events, and then hand the call over to Mark Wilson for a review of our financials. Lend as always by taking your questions. As some of you may know, November 1st was Afromegaly Awareness Day. We commemorated this day by hosting acromegaly patients at our headquarters to bring life to the impact of our mission of improving patients' lives. That was the picture you saw on the first slide of our presentation today. It was especially timely for Krenetics as we recently submitted our first NDA for our investigational drug, paltucetine, for the treatment and long-term maintenance of acromegaly. We very much look forward to Acromegaly Awareness Day next November. We believe paltucetine will represent a next generation therapy for people living with acromegaly. We expect to receive the FDA filing notification later in December and expect a standard review period. In the meantime, we continue to focus on building our commercial capabilities and preparing for the anticipated launch of our first drug next fall. As part of these preparations, our national accounts team is meeting with payers to discuss formulary placement and product coverage. We believe that having these conversations early and often allows us to positively influence formulary placement and coverage decisions with the goal of broad access for patients living with acromegaly. In addition, our medical science liaisons are in the field speaking with academic KOLs and community endocrinologists to get their feedback from these clinicians on how treatment protocols are established within their practices and to better understand the patient experience.